KP496 is a selective dual antagonist of leukotriene D4 (LTD4) and thromboxane A2 (TXA2) receptors; it significantly inhibits both acute (day 7) and chronic (day 21) lung inflammation; attenuates the number of lymphocytes on day 7 and macrophages, neutrophils, and eosinophils on days 7 and 21; significantly suppresses the increase of hydroxy-L-proline content in the lung (with an inhibition ratio of approximately 74% compared to vehicle control); and reduces infiltration of total cells, eosinophils, monocytes/macrophages, and lymphocytes in the lung.